We are studying and comparing two different treatments for stages II-III breast cancer to find out which is the more effective. In this study, we are comparing neoadjuvant chemotherapy alone with treatment with neoadjuvant chemotherapy PLUS an immunotherapy drug called durvalumab.
Thank you for your interest, but this study will start enrolling soon.
North Carolina (Statewide)
Anureet Copeland
UNC Hospitals - Rex
Clinical or Medical
Interventional
Cancer (Breast)
23-2910
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
